We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pfizer Announces Settlement and License Agreement with Mylan Related to Vfend®
News

Pfizer Announces Settlement and License Agreement with Mylan Related to Vfend®

Pfizer Announces Settlement and License Agreement with Mylan Related to Vfend®
News

Pfizer Announces Settlement and License Agreement with Mylan Related to Vfend®

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pfizer Announces Settlement and License Agreement with Mylan Related to Vfend®"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pfizer Inc has announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal agent. The agreement is limited to the tablet form of Vfend and does not cover Pfizer’s Vfend products for intravenous use or oral suspension.

Pursuant to the agreement, Mylan will have the right to market voriconazole tablets in the United States in the first quarter of 2011. Additional details of the agreement with Mylan remain confidential. The agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Advertisement